Select the search type
  • Site
  • Web
Search

Featured Fund

PUBLIC ASEAN GROWTH FUND (PASGF)
Fund Objective
To achieve capital growth over the medium to long-term period by investing in a portfolio of investments in ASEAN markets.
3-Year
Fund Volatility
16.7
very high
Lipper Analytics
10 Jun 2022
Launch Date
26 October 2017
Performance of PASGF vs its Benchmark Index Over the Following Periods Ended 30/06/2022
PASGF (%) Benchmark (%) PASGF (%) Benchmark (%)
Total Return Annualised Return
0.86 3.17 0.86 3.17
5.48 -11.63 1.79 -4.03
- - - -
- - - -
9.45 -6.65 1.97 -1.48
*Source: Lipper, as at 30 Jun 2022
Performance of PASGF and Benchmark Index (Since Fund Commencement* to 30/06/2022)
FTSE/ASEAN 40 Index
* Commencement Date - 15 November 2017


  • Public ASEAN Growth Fund (PASGF or the Fund) seeks to achieve capital growth over the medium to long-term period by investing in a portfolio of investments in ASEAN markets.
  • As at 31 May 2022, 90.3% of PASGF ’s net asset value (NAV) was invested in equities while 9.7% of NAV was invested in money market instruments. The Fund focused on sectors such as Financial, Consumer, Energy and Basic Materials across the ASEAN markets.
  • From its commencement on 15 November 2017 up to 31 May 2022, the Fund registered a total return of +18.72% to outperform its benchmark ’s return of +1.39%. This outperformance was led by the Fund ’s selected investments in the Financial and Consumer sectors which are leveraged to the resilient domestic demand and consumer spending within the region.
  • For the 3-year period ended 31 May 2022, the Fund registered a return of +20.65% to also outperform its benchmark ’s return of +1.52%.
  • Going forward, the Fund may look to be positioned in sectors such as Financials which stand to benefit from the current environment of rising interest rates, Basic Materials stocks which stand to benefit from elevated material prices, as well as the Consumer sector which stands to benefit from the re-opening of international borders globally.


Our investment disclaimer can be viewed here.